30.13
price up icon2.87%   +0.84
after-market  After Hours:  30.13 
loading
Omnicell, Inc. stock is currently priced at $30.13, with a 24-hour trading volume of 863.39K. It has seen a +2.87% increased in the last 24 hours and a +9.29% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $28.61 pivot point. If it approaches the $30.32 resistance level, significant changes may occur.
Previous Close:
$29.29
Open:
$29.87
24h Volume:
863.39K
Market Cap:
$1.38B
Revenue:
$1.15B
Net Income/Loss:
$-20.37M
P/E Ratio:
-39.13
EPS:
-0.77
Net Cash Flow:
$126.08M
1W Performance:
+8.15%
1M Performance:
+9.29%
6M Performance:
-1.02%
1Y Performance:
-54.99%
1D Range:
Value
$29.35
$30.74
52W Range:
Value
$25.69
$77.14

Omnicell, Inc. Stock (OMCL) Company Profile

Name
Name
Omnicell, Inc.
Name
Phone
650-251-6100
Name
Address
590 East Middlefield Road, Mountain View
Name
Employee
2,430
Name
Twitter
@Omnicell
Name
Next Earnings Date
2024-05-15
Name
Latest SEC Filings
Name
OMCL's Discussions on Twitter

Omnicell, Inc. Stock (OMCL) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-03-24 Initiated Barclays Underweight
Nov-03-23 Downgrade BTIG Research Buy → Neutral
Nov-03-23 Upgrade Piper Sandler Neutral → Overweight
Nov-03-23 Upgrade Wells Fargo Underweight → Equal Weight
Oct-11-23 Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Sep-26-23 Reiterated Wells Fargo Underweight
Aug-02-23 Downgrade Piper Sandler Overweight → Neutral
Jul-20-23 Downgrade Wells Fargo Overweight → Underweight
Feb-27-23 Upgrade The Benchmark Company Hold → Buy
Nov-03-22 Downgrade The Benchmark Company Buy → Hold
Sep-16-22 Initiated KeyBanc Capital Markets Overweight
Sep-09-22 Initiated BofA Securities Buy
Jul-15-22 Initiated SVB Leerink Mkt Perform
Dec-06-21 Resumed Wells Fargo Overweight
Jun-09-21 Initiated JP Morgan Neutral
May-24-21 Initiated BTIG Research Buy
Feb-02-21 Upgrade Piper Sandler Neutral → Overweight
Dec-08-20 Initiated Berenberg Buy
Dec-03-20 Downgrade Cantor Fitzgerald Overweight → Neutral
Jul-07-20 Initiated Stephens Overweight
Feb-07-20 Reiterated Dougherty & Company Buy
Nov-21-19 Reiterated Dougherty & Company Buy
Jul-26-19 Upgrade Craig Hallum Hold → Buy
Mar-07-19 Reiterated Dougherty & Company Buy
Jun-29-18 Resumed The Benchmark Company Buy
Sep-05-17 Reiterated The Benchmark Company Buy
Jul-28-17 Reiterated Dougherty & Company Buy
Apr-21-17 Downgrade Piper Jaffray Overweight → Neutral
Jan-19-17 Initiated Dougherty & Company Buy
Dec-06-16 Reiterated The Benchmark Company Buy
Jul-07-16 Reiterated FBR Capital Outperform
Mar-21-16 Reiterated Topeka Capital Markets Buy
Jan-07-16 Initiated The Benchmark Company Buy
Nov-16-15 Reiterated Topeka Capital Markets Buy
Oct-30-15 Reiterated FBR Capital Outperform
Sep-28-15 Upgrade Sidoti Neutral → Buy
Jul-31-15 Reiterated Topeka Capital Markets Buy
View All

Omnicell, Inc. Stock (OMCL) Financials Data

Omnicell, Inc. (OMCL) Revenue 2024

OMCL reported a revenue (TTM) of $1.15 billion for the quarter ending December 31, 2023, a -11.48% decline year-over-year.
loading

Omnicell, Inc. (OMCL) Net Income 2024

OMCL net income (TTM) was -$20.37 million for the quarter ending December 31, 2023, a -460.68% decrease year-over-year.
loading

Omnicell, Inc. (OMCL) Cash Flow 2024

OMCL recorded a free cash flow (TTM) of $126.08 million for the quarter ending December 31, 2023, a +639.85% increase year-over-year.
loading

Omnicell, Inc. (OMCL) Earnings per Share 2024

OMCL earnings per share (TTM) was -$0.45 for the quarter ending December 31, 2023, a -550.00% decline year-over-year.
loading
Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
$17.60
price down icon 0.06%
$31.72
price down icon 1.09%
health_information_services EVH
$27.10
price down icon 1.13%
health_information_services TXG
$27.48
price up icon 4.53%
$24.09
price down icon 0.95%
health_information_services RCM
$12.47
price up icon 0.16%
Cap:     |  Volume (24h):